Voyager Therapeutics (VYGR) Total Non-Current Liabilities (2014 - 2024)

Voyager Therapeutics (VYGR) has 11 years of Total Non-Current Liabilities data on file, last reported at $56.4 million in Q3 2024.

• For the quarter ending Q3 2024, Total Non-Current Liabilities fell 43.36% year-over-year to $56.4 million; the trailing twelve-month figure through Sep 2024 stood at $56.4 million (down 43.36% YoY), and the FY2023 full-year result was $96.9 million, up 22.55% from the prior year.
• Total Non-Current Liabilities retreated to $56.4 million in Q3 2024, from $59.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $211.8 million in Q1 2020 to a low of $56.3 million in Q3 2021.
• A 5-year average of $91.5 million and a median of $80.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities tumbled 72.44% in 2021 and soared 88.68% in 2022, its largest moves.
• Tracing VYGR's Total Non-Current Liabilities over 5 years: stood at $62.9 million in 2020, then fell by 5.83% to $59.2 million in 2021, then jumped by 33.54% to $79.0 million in 2022, then increased by 22.55% to $96.9 million in 2023, then slumped by 41.81% to $56.4 million in 2024.
• Business Quant data shows VYGR's Total Non-Current Liabilities at $56.4 million in Q3 2024, $59.6 million in Q2 2024, and $85.7 million in Q1 2024.